X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Natco Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs NATCO PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. NATCO PHARMA FRESENIUS KABI ONCO./
NATCO PHARMA
 
P/E (TTM) x 22.1 23.5 94.1% View Chart
P/BV x 3.1 17.8 17.5% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 FRESENIUS KABI ONCO.   NATCO PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
NATCO PHARMA
Mar-14
FRESENIUS KABI ONCO./
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs176877 20.1%   
Low Rs79424 18.5%   
Sales per share (Unadj.) Rs37.7223.4 16.9%  
Earnings per share (Unadj.) Rs5.131.1 16.4%  
Cash flow per share (Unadj.) Rs6.740.3 16.7%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.5219.5 19.4%  
Shares outstanding (eoy) m158.2333.07 478.5%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x3.42.9 116.0%   
Avg P/E ratio x25.020.9 119.4%  
P/CF ratio (eoy) x18.916.1 117.2%  
Price / Book Value ratio x3.03.0 101.0%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m20,13521,504 93.6%   
No. of employees `0001.2NA-   
Total wages/salary Rs m7031,128 62.4%   
Avg. sales/employee Rs Th5,176.2NM-  
Avg. wages/employee Rs Th610.4NM-  
Avg. net profit/employee Rs Th699.6NM-  
INCOME DATA
Net Sales Rs m5,9637,389 80.7%  
Other income Rs m18167 10.8%   
Total revenues Rs m5,9817,556 79.2%   
Gross profit Rs m1,4301,793 79.7%  
Depreciation Rs m258304 84.7%   
Interest Rs m-26366 -7.1%   
Profit before tax Rs m1,2161,290 94.3%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342309 110.9%   
Profit after tax Rs m8061,027 78.4%  
Gross profit margin %24.024.3 98.8%  
Effective tax rate %28.123.9 117.6%   
Net profit margin %13.513.9 97.2%  
BALANCE SHEET DATA
Current assets Rs m5,1023,681 138.6%   
Current liabilities Rs m2,3853,123 76.4%   
Net working cap to sales %45.67.6 602.6%  
Current ratio x2.11.2 181.4%  
Inventory Days Days15089 167.7%  
Debtors Days Days11359 193.0%  
Net fixed assets Rs m5,1487,685 67.0%   
Share capital Rs m158331 47.8%   
"Free" reserves Rs m6,5566,670 98.3%   
Net worth Rs m6,7327,259 92.7%   
Long term debt Rs m952955 99.7%   
Total assets Rs m10,38811,957 86.9%  
Interest coverage x-45.84.5 -1,012.3%   
Debt to equity ratio x0.10.1 107.5%  
Sales to assets ratio x0.60.6 92.9%   
Return on assets %7.511.7 64.4%  
Return on equity %12.014.2 84.6%  
Return on capital %14.620.7 70.5%  
Exports to sales %74.539.4 189.2%   
Imports to sales %24.85.7 434.6%   
Exports (fob) Rs m4,4412,908 152.7%   
Imports (cif) Rs m1,477421 350.8%   
Fx inflow Rs m5,2983,445 153.8%   
Fx outflow Rs m1,772703 252.2%   
Net fx Rs m3,5252,743 128.5%   
CASH FLOW
From Operations Rs m1,2741,440 88.5%  
From Investments Rs m-1,204-1,089 110.6%  
From Financial Activity Rs m-196-353 55.6%  
Net Cashflow Rs m-126-1 8,476.5%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 81.0 1.5 5,510.2%  
Indian inst/Mut Fund % 0.3 7.8 3.8%  
FIIs % 9.6 16.6 57.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 26.0 35.0%  
Shareholders   42,599 25,395 167.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   PLETHICO PHARMA  AJANTA PHARMA  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS